

This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
Neurology				
Depression	Histone deacetylase (HDAC)	<p>Studies in mice suggest that HDAC inhibitors could help treat depression. In a mouse model of depression, direct infusion of two different HDAC inhibitors into the brain's nucleus accumbens led to less depressive-like behavior than infusion of vehicle. Next steps include designing HDAC inhibitors specific for HDAC isoforms implicated in psychiatric disorders.</p> <p>Merck & Co. Inc. markets the HDAC inhibitor Zolinza vorinostat to treat cutaneous T cell lymphoma (CTCL).</p> <p>Istodax romidepsin, an HDAC inhibitor from Gloucester Pharmaceuticals Inc., is in registration to treat CTCL.</p> <p>TopoTarget A/S' HDAC inhibitor belinostat is in Phase III testing to treat peripheral T cell lymphoma and Phase II testing to treat CTCL, acute myelogenous leukemia (AML) and various types of solid tumors.</p> <p>SciBX 2(38); doi:10.1038/scibx.2009.1447 Published online Oct. 1, 2009</p>	Findings unpatented; unavailable for licensing	<p>Covington, H.E. III <i>et al. J. Neurosci.</i>; published online Sept. 16, 2009; doi:10.1523/JNEUROSCI.1758-09.2009</p> <p>Contact: Eric J. Nestler, Mount Sinai School of Medicine, New York, N.Y. e-mail: eric.nestler@mssm.edu</p>